New 3D MRI scan could replace needle test for liver patients

NCT ID NCT06205992

Recruiting now Diagnosis Sponsor: Shengjing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 3D MRI scan (3D-MRE) is better than a standard 2D MRI scan at detecting liver scarring (cirrhosis) and high blood pressure in the liver (portal hypertension). Researchers will compare both scans to the current gold-standard catheter measurement in 100 adults with confirmed cirrhosis. If 3D-MRE proves accurate, it could offer a safer, non-invasive way to monitor liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnetic resonance elastography (MRE) scan
What this could lead to: If successful, this could provide a non-invasive way to assess liver disease severity, reducing the need for risky catheter procedures.
What could go wrong: This is an early-stage diagnostic study with only 100 participants. The new scan method may not prove accurate enough to replace current tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS LIVER PORTAL HYPERTENSION

Contacts and locations

Locations

Shengjing Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.